{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:50:45Z","timestamp":1792011045794,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.maturitas.2017.08.008","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T01:02:11Z","timestamp":1503018131000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Skeletal health in breast cancer survivors"],"prefix":"10.1016","volume":"105","author":[{"given":"Olivier","family":"Bruy\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.maturitas.2017.08.008_bib0005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.maturitas.2017.08.008_bib0010","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2017.08.008_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"T.A.o.i.C.T.G. Arimidex","year":"2008","journal-title":"Lancet Oncol."},{"issue":"10001","key":"10.1016\/j.maturitas.2017.08.008_bib0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"G. Early Breast Cancer Trialists' Collaborative","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.maturitas.2017.08.008_bib0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2147\/CIA.S3466","article-title":"Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer","volume":"3","author":"Gonnelli","year":"2008","journal-title":"Clin. Interv. Aging"},{"issue":"3","key":"10.1016\/j.maturitas.2017.08.008_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ecl.2011.05.008","article-title":"Management of bone disease in patients undergoing hormonal therapy for breast cancer","volume":"40","author":"Mirza","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"3","key":"10.1016\/j.maturitas.2017.08.008_bib0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.maturitas.2014.08.001","article-title":"Screening for osteoporosis after breast cancer: for whom, why and when","volume":"79","author":"Tremollieres","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2017.08.008_bib0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/1471-2407-11-384","article-title":"Increased fracture rate in women with breast cancer: a review of the hidden risk","volume":"11","author":"Body","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.maturitas.2017.08.008_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-013-2431-3","article-title":"Bone mineral density and risk of breast cancer in postmenopausal women","volume":"138","author":"Qu","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.maturitas.2017.08.008_bib0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a116515","article-title":"Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures","volume":"136","author":"Olsson","year":"1992","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.maturitas.2017.08.008_bib0055","first-page":"523","article-title":"Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden)","volume":"5","author":"Persson","year":"1994","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.maturitas.2017.08.008_bib0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.breast.2011.09.001","article-title":"Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer","volume":"21","author":"Servitja","year":"2012","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.maturitas.2017.08.008_bib0065","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol."},{"issue":"9453","key":"10.1016\/j.maturitas.2017.08.008_bib0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.maturitas.2017.08.008_bib0080","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.maturitas.2017.08.008_bib0085","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Aebi","year":"2010","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2017.08.008_bib0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2017.08.008_bib0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.maturitas.2017.08.008_bib0100","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer \u2212 a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer","volume":"61","author":"Bruning","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1005792830054","article-title":"Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications","volume":"43","author":"Del Mastro","year":"1997","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.maturitas.2017.08.008_bib0115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.maturitas.2017.08.008_bib0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.maturitas.2017.08.008_bib0125","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.maturitas.2017.08.008_bib0135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.maturitas.2017.08.008_bib0140","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.maturitas.2017.08.008_bib0145","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann. Oncol."},{"issue":"9922","key":"10.1016\/j.maturitas.2017.08.008_bib0150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"9992","key":"10.1016\/j.maturitas.2017.08.008_bib0155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2017.08.008_bib0160","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00223-017-0266-3","article-title":"Osteoporosis in frail patients: a consensus paper of the belgian bone club","volume":"101","author":"Gielen","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.maturitas.2017.08.008_bib0170","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"10001","key":"10.1016\/j.maturitas.2017.08.008_bib0175","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.maturitas.2017.08.008_bib0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2017.08.008_bib0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0021-9681(87)90061-0","article-title":"Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study","volume":"40","author":"Utz","year":"1987","journal-title":"J. Chron. Dis."},{"issue":"7\u20138","key":"10.1016\/j.maturitas.2017.08.008_bib0190","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.maturitas.2017.08.008_bib0195","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1047-2797(03)00056-5","article-title":"Low risk of hip fracture among elderly breast cancer survivors","volume":"13","author":"Lamont","year":"2003","journal-title":"Ann. Epidemiol."},{"issue":"5","key":"10.1016\/j.maturitas.2017.08.008_bib0200","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2017.08.008_bib0205","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/jbmr.1556","article-title":"Fracture risk in women with breast cancer: a population-based study","volume":"27","author":"Melton","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.maturitas.2017.08.008_bib0210","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/jgs.12269","article-title":"Fracture risk in older, long-term survivors of early-stage breast cancer","volume":"61","author":"Pawloski","year":"2013","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.maturitas.2017.08.008_bib0215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/jca.10288","article-title":"Spatial and temporal fracture pattern in breast and gynecologic cancer survivors","volume":"6","author":"Hui","year":"2015","journal-title":"J. Cancer"},{"issue":"11","key":"10.1016\/j.maturitas.2017.08.008_bib0220","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjc.2016.314","article-title":"Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study","volume":"115","author":"Colzani","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.maturitas.2017.08.008_bib0225","doi-asserted-by":"crossref","first-page":"e75109","DOI":"10.1371\/journal.pone.0075109","article-title":"Fracture in asian women with breast cancer occurs at younger age","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217307867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512217307867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:12:14Z","timestamp":1759914734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512217307867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":45,"alternative-id":["S0378512217307867"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.08.008","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal health in breast cancer survivors","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}